Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128693) titled 'A single-arm, prospective phase 2 clinical study on the treatment of POEMS syndrome with low-frequency esatuximab combined with lenalidomide and dexamethasone regimen' on July 24.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Condition: POEMS syndrome

Intervention: Intervention group:The low-frequency extuximab combined with lenalidomide and dexamethasone regimen (the administration of extuximab is 10mg/kg, once every 2 weeks from the first to the fourth week, and then every 4 weeks thereafter once every 8 w...